10 Best Pharma Stocks to Buy for Long Term Growth

7. Pacira Biosciences, Inc. (NASDAQ:PCRX)

Number of Hedge Fund Holders: 30 

Pacira BioSciences, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on developing non-opioid pain management solutions, with its primary product being Exparel, a long-acting local analgesic for postsurgical pain. The business sells Exparel directly to medical facilities such as hospitals and surgery centers. Because of its dedication to non-opioid medicines, the company stands out in the business. The company wants to solve the opioid crisis and decrease opioid consumption by providing safer options for pain management.

Pacira BioSciences, Inc. (NASDAQ:PCRX) reported a record total revenue of $701 million for 2024, which was driven by solid sales performance across its key products. EXPAREL led the way with $147.7 million in revenue, followed by ZILRETTA at $33.1 million and iovera at $6.5 million—all showing steady growth from the previous year. The company reported a strong non-GAAP gross margin of 79% for Q4 and ended the year with $485 million in cash and investments.

Looking ahead, Pacira BioSciences, Inc. (NASDAQ:PCRX) projects 2025 revenue between $725 million and $765 million. This growth outlook is supported by expanding demand for its non-opioid pain management solutions, a market that continues to grow amid rising awareness of opioid addiction risks. As one of the best pharmaceutical stocks focused on innovative pain therapies, Pacira is positioning itself for long-term growth. While SG&A expenses increased due to investments in commercial and medical operations, these initiatives are expected to support long-term growth and broader market access.

Investor confidence is bolstered by the company’s strategic focus on innovation and access. The company received the RMAT designation from the FDA for PCRX-201, backed by promising two-year Phase 1 data. Additionally, the business has secured separate CMS coverage and product-specific reimbursement codes for both EXPAREL and iovera, simplifying billing and improving accessibility. These developments, alongside a strong product lineup and commitment to non-opioid therapies, position Pacira BioSciences, Inc. (NASDAQ:PCRX) for continued success in the evolving pain management landscape.